Hadrien Bouchez

Principal, Kurma Life Sciences Partners – Board member
Linkedin

Hadrien has been in charge of different positions at Kurma (analyst, associate and now as principal). He has participated in a dozen investments of the Kurma Biofund II and III funds. Hadrien has actively contributed in particular to the creation of several portfolio companies such as Dynacure, Imcheck Therapeutics, Flamingo Therapeutics, Ermium Therapeutics and Corlieve Therapeutics. Hadrien holds a PharmD from the Faculty of Pharmacy, Lille, and a Master in Entrepreneurship from the ESSEC Business School.

Management team

Scientific Advisor

Jean-Philippe Herbeuval, PhD

Jean-Philippe Herbeuval, PhD

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris

Board Of Directors​

Scientific Advisory Board

Jean-Philippe Herbeuval, PhD

Jean-Philippe Herbeuval, PhD

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Michel Bouvier, PhD

Michel Bouvier, PhD

Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal
Martine Smit, PhD

Martine Smit, PhD

Professor of Target and Systems Biochemistry at the Faculty of Science of the Vrije Universiteit Amsterdam

Graeme Milligan, PhD

Gardiner Professor of Biochemistry, and Deputy Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow
Linkedin

About Us

Science

Support & contact

Ermium Therapeutics © 2023 All Rights Reserved

Design by Cédric Adam

close